Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults

The tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib were recently approved in Canada for the treatment of solid tumours harbouring neurotrophic tyrosine receptor kinase (<i>NTRK)</i> gene fusions. These <i>NTRK</i> gene fusions are oncogenic drivers fo...

Full description

Bibliographic Details
Main Authors: D. Gwyn Bebb, Shantanu Banerji, Normand Blais, Patrice Desmeules, Sharlene Gill, Andrea Grin, Harriet Feilotter, Aaron R. Hansen, Martin Hyrcza, Monika Krzyzanowska, Barbara Melosky, Jonathan Noujaim, Bibiana Purgina, Dean Ruether, Christine E. Simmons, Denis Soulieres, Emina Emilia Torlakovic, Ming-Sound Tsao
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Current Oncology
Subjects:
NTRK
larotrectinib
entrectinib
targeted therapy
molecular testing
oncogenic drivers
Online Access:https://www.mdpi.com/1718-7729/28/1/53

Internet

https://www.mdpi.com/1718-7729/28/1/53

Similar Items